Stoke Therapeutics to Participate at Upcoming March Investor Conferences

Rhea-AI Summary

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology firm focused on treating severe diseases by enhancing protein expression through RNA-based therapies. The company will participate in two upcoming investor conferences: the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 12:50 p.m. ET, and the 2nd Annual Needham Virtual Neuroscience Forum on March 15, 2023, at 3:20 p.m. ET. Live webcasts and replays will be accessible on Stoke's investor website. Stoke is known for its proprietary TANGO technology and is developing treatments for conditions like Dravet syndrome and autosomal dominant optic atrophy (ADOA). More details can be found on their website.

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will be participating at the following upcoming investor conferences:

Cowen 43rd Annual Health Care Conference
Date: Monday, March 6, 2023
Time: 12:50 p.m. ET

2nd Annual Needham Virtual Neuroscience Forum
Date: Wednesday, March 15, 2023
Time: 3:20 p.m. ET

Live webcasts of each event and an archived replay of the webcasts following each event, will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/.

About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow Stoke on Twitter at @StokeTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005745/en/

Stoke Investor Contact:

Eric Rojas

Vice President, Investor Relations

IR@stoketherapeutics.com

617-312-2754

Source: Stoke Therapeutics, Inc.

FAQ

What conferences is Stoke Therapeutics participating in March 2023?

Stoke Therapeutics is participating in the Cowen 43rd Annual Health Care Conference on March 6, 2023, and the 2nd Annual Needham Virtual Neuroscience Forum on March 15, 2023.

What is the ticker symbol for Stoke Therapeutics?

The ticker symbol for Stoke Therapeutics is STOK.

Where can I find the live webcasts for Stoke Therapeutics' conferences?

The live webcasts for Stoke Therapeutics' conferences can be found on their investor website.

What is the focus of Stoke Therapeutics' research and development?

Stoke Therapeutics focuses on upregulating protein expression to treat severe diseases, particularly those caused by haploinsufficiency.

What is the purpose of Stoke’s TANGO technology?

Stoke's TANGO technology aims to develop antisense oligonucleotides to selectively restore protein levels in diseases.